Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 55-60

  Richhariya, Akshara ^a   Qian, Yi ^a   Zhao, Yufan ^a   Chung, Karen ^a  

^a AMGEN INC   (United States)

Author keywords

Bisphosphonates; Intravenous administration; Time and motion; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYDRATION; INFUSION TIME; MALE; PROSTATE CANCER; TIME; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84863296801     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S27693     Document Type: Article

References (17)

1. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9 Suppl 4:14-27.
2. James ND, Bloomfield D, Luscombe C. The changing pattern of management for hormone-refractory, metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2006;9(3):221-229.
3. Janjan N. Bone metastases: approaches to management. Semin Oncol. 2001;28(4 Suppl 11):28-34.
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s-6249s.
5. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-1468.
6. Zometa® (zoledronic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
7. DesHarnais CL, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer. 2001;9(7):545-551.
8. Dranitsaris G, Castel LD, Baladi JF, Schulman KA. Zoledronic acid versus pamidronate as palliative therapy in cancer patients: a Canadian time and motion analysis. J Oncol Pharm Prac. 2001;7(1):27-33.
9. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20(17):3719-3736.
10. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol. 2000;18(6):1378-1391.
11. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042-4057.
12. Yabroff KR, Warren JL, Knopf K, Davis WW, Brown ML. Estimating patient time costs associated with colorectal cancer care. Med Care. 2005;43(7):640-648.
13. Barrett-Lee P, Bloomfield D, Dougherty L, et al. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting. Curr Med Res Opin. 2007;23(7):1575-1582.
14. Schivazappa C, Baldini E, Cortesi E, Dauria G, Rolia F, Berto P. Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study. Recenti Prog Med. 2007;98(1):12-15.
15. Wardley A, Body JJ, Neary M. A time-in-motion study of oral ibandronate versus IV zoledronic acid for treatment of metastatic bone disease in breast cancer patients. J Clin Oncol. 2005;23(Suppl 1):6123.
16. Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncol. 2009;6(11):494-505.
17. Fletcher RW, Fletcher SW. Clinical epidemiology. The essentials. 4th ed. Baltimore: Lippincott Williams & Wilkins; 2005.